Skip to main content
ENCell Co., Ltd. logo

ENCell Co., Ltd. — Investor Relations & Filings

Ticker · 456070 ISIN · KR7456070002 KO Manufacturing
Open in API
Filings indexed 89 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 456070

About ENCell Co., Ltd.

http://www.encellinc.com/en/

ENCell Co., Ltd. is a biopharmaceutical company specializing in advanced cell and gene therapies (CGT). The company's primary focus is providing Contract Development and Manufacturing Organization (CDMO) services, supported by globally recognized GMP facilities. Its offerings include process development, manufacturing, and contract quality testing (CQT) for a diverse portfolio of advanced therapies, including MSC, CAR-T, CAR-NK, and iPSC-derived cell therapies. ENCell leverages proprietary technologies such as the ROCKET Platform for multi-product GMP production and a next-generation stem cell platform designed to enhance yield and efficacy. In addition to its CDMO business, the company develops its own therapeutic pipeline. This internal research and development focuses on next-generation stem cell treatments, cancer immunotherapy, and AAV-based gene therapies, with a program for Duchenne Muscular Dystrophy in development.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 95% confidence The document is clearly titled “분기보고서” (Quarterly Report) for the period January 1 to March 31, 2026 (제9기). It contains full financial statements (balance sheet, income statement, cash flows), management’s discussion and analysis, auditor’s opinion, and detailed business and corporate governance sections. This is not merely an announcement or summary but the actual interim/quarterly report. Therefore, it should be classified as Interim / Quarterly Report. Q1 2026
2026-05-15 Korean
단일판매ㆍ공급계약체결
Regulatory Filings Classification · 85% confidence The document is a public regulatory announcement of a single sales and supply contract entered into on 2026-04-20, detailing contract sums, counterparty, term, and key payment conditions. It does not constitute a financial report (10-K, IR), earnings release, M&A filing, dividend notice, or share transaction, nor does it fit any more specific category in our taxonomy. Therefore, it is best classified under the fallback category for miscellaneous regulatory disclosures: Regulatory Filings (RNS).
2026-04-20 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 95% confidence The document is the Korean “주식등의 대량보유상황보고서(약식)” – a detailed large‐shareholding report filed under the Capital Markets Act, listing shareholding percentages, changes, reporting person and related entities. This matches our definition for a Major Shareholding Notification (Code: MRQ).
2026-04-15 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 99% confidence The document is a ‘주식등의 대량보유상황보고서(일반)’ filed under Korea’s Capital Markets Act, detailing the number of shares held and changes by the reporting person and related parties, including threshold percentages, purposes for holding, and reasons for changes. It is a mandatory disclosure of significant ownership levels and their movements. This matches the definition of a Major Shareholding Notification.
2026-04-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 87% confidence The document is a mandatory insider report (“임원ㆍ주요주주 특정증권등 소유상황보고서”) filed by an officer (백광문) of 이엔셀 주식회사, disclosing his personal holdings and transactions in the company’s shares and stock options. It details acquisition and disposition of securities by a director, matching the definition of a Director’s Dealing report. Therefore, it falls under the “DIRS” category.
2026-04-02 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 95% confidence The document is a formal notification to the Financial Services Commission/KRX titled “사외이사의 선임ㆍ해임 또는 중도퇴임에 관한 신고,” detailing the appointment of a new outside director, the date of change, number of directors changed, and biographical data. This clearly describes a change in the company’s board of directors rather than a financial report or share transaction. As such, it fits the “Board/Management Information” category (Code: MANG).
2026-03-31 Korean

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.